» Articles » PMID: 15280445

P63 and P73: Roles in Development and Tumor Formation

Overview
Journal Mol Cancer Res
Specialty Cell Biology
Date 2004 Jul 29
PMID 15280445
Citations 200
Authors
Affiliations
Soon will be listed here.
Abstract

The tumor suppressor p53 is critically important in the cellular damage response and is the founding member of a family of proteins. All three genes regulate cell cycle and apoptosis after DNA damage. However, despite a remarkable structural and partly functional similarity among p53, p63, and p73, mouse knockout studies revealed an unexpected functional diversity among them. p63 and p73 knockouts exhibit severe developmental abnormalities but no increased cancer susceptibility, whereas this picture is reversed for p53 knockouts. Neither p63 nor p73 is the target of inactivating mutations in human cancers. Genomic organization is more complex in p63 and p73, largely the result of an alternative internal promoter generating NH2-terminally deleted dominant-negative proteins that engage in inhibitory circuits within the family. Deregulated dominant-negative p73 isoforms might play an active oncogenic role in some human cancers. Moreover, COOH-terminal extensions specific for p63 and p73 enable further unique protein-protein interactions with regulatory pathways involved in development, differentiation, proliferation, and damage response. Thus, p53 family proteins take on functions within a wide biological spectrum stretching from development (p63 and p73), DNA damage response via apoptosis and cell cycle arrest (p53, TAp63, and TAp73), chemosensitivity of tumors (p53 and TAp73), and immortalization and oncogenesis (DeltaNp73).

Citing Articles

Development of a Novel Prognostic Model for Lung Adenocarcinoma Utilizing Pyroptosis-Associated LncRNAs.

Bai H, Li T, Sun L, Zhang J, Kang X, Qu Y Anal Cell Pathol (Amst). 2025; 2025():4488139.

PMID: 39834603 PMC: 11745560. DOI: 10.1155/ancp/4488139.


Immunohistochemical analysis of p53 and p63 in selected odontogenic cysts and tumours.

Bartake A, Sarode S, Krishnapillai R, Sarode G, Narang B, Hallikeri K J Oral Maxillofac Pathol. 2024; 28(2):186-191.

PMID: 39157832 PMC: 11329081. DOI: 10.4103/jomfp.jomfp_417_23.


How MicroRNAs Command the Battle against Cancer.

Wu H, Leng S, Sergi C, Leng R Int J Mol Sci. 2024; 25(11).

PMID: 38892054 PMC: 11172831. DOI: 10.3390/ijms25115865.


Identification and clinicopathological analysis of potential p73-regulated biomarkers in colorectal cancer via integrative bioinformatics.

Bareja C, Dwivedi K, Uboveja A, Mathur A, Kumar N, Saluja D Sci Rep. 2024; 14(1):9894.

PMID: 38688978 PMC: 11061124. DOI: 10.1038/s41598-024-60715-1.


TP63 truncating mutation causes increased cell apoptosis and premature ovarian insufficiency by enhanced transcriptional activation of CLCA2.

Fan Y, Chen S, Chu C, Yin X, Jin J, Zhang L J Ovarian Res. 2024; 17(1):67.

PMID: 38528613 PMC: 10962206. DOI: 10.1186/s13048-024-01396-2.